Glecaprevir/pibrentasvir

Glecaprevir/pibrentasvir (G/P), sold under the brand names Mavyret and Maviret, is a fixed-dose combination medication used to treat hepatitis C. It contains glecaprevir and pibrentasvir. It works against all six types of hepatitis C. At twelve weeks following treatment between 81% and 100% of people have no evidence of hepatitis C. It is taken once a day by mouth with food.

Glecaprevir/pibrentasvir
Combination of
GlecaprevirNS3/NS4A inhibitor
PibrentasvirNS5A inhibitor
Clinical data
Trade namesMavyret, Maviret, others
AHFS/Drugs.comMonograph
MedlinePlusa617039
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
KEGG

The most common side effects are headache, diarrhea, and tiredness. In those with a history of hepatitis B, reactivation may occur. It is not recommended in people with moderate to severe liver disease. Glecaprevir works by blocking the protein NS3/4A protease, while pibrentasvir works by blocking NS5A.

The combination was approved for medical use in the United States and Europe in 2017. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.